Literature DB >> 15538044

Clinical experience with axillary presentation breast cancer.

Viviana Galimberti1, Gulliermo Bassani, Simonetta Monti, Serife Simsek, Gaetano Villa, Giuseppe Renne, Alberto Luini.   

Abstract

We present our experience of 50 cases of occult primary tumours presenting as axillary metastases, all with histological report of adenocarcinoma compatible with mammary carcinoma. After bilateral US and mammography, with MRI and mammoscintigraphy where necessary, ipsilateral breast cancer was suspected in 23 cases and quadrantectomy performed. Breast cancer was found only in 12 (24%). In the other 27 women there was no clinical or instrumental suspicion of breast cancer or other primary disease site, so the main treatment was complete axillary dissection plus radiotherapy to the ipsilateral breast (given to all patients). Chemotherapy alone was given to 27 patients, hormone treatment to 5 patients, and both to 18. Mean follow-up is 41.3 months (range 108-1). Thirty-nine (84%) patients are alive with no evidence of disease, two are alive with breast disease, five patients have died of metastatic disease (with no evidence breast disease). Our experience, like that of the literature, confirms that the breast should be extensively investigated but that blanket investigations are not usually revealing. We present guidelines for the work-up of patients presenting with axillary disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538044     DOI: 10.1007/s10549-004-9453-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Indications for breast magnetic resonance imaging. Consensus document "Attualità in senologia", Florence 2007.

Authors:  F Sardanelli; G M Giuseppetti; G Canavese; L Cataliotti; S Corcione; E Cossu; M Federico; L Marotti; L Martincich; P Panizza; F Podo; M Rosselli Del Turco; C Zuiani; C Alfano; M Bazzocchi; P Belli; S Bianchi; A Cilotti; M Calabrese; L Carbonaro; L Cortesi; C Di Maggio; A Del Maschio; A Esseridou; A Fausto; M Gennaro; R Girometti; R Ienzi; A Luini; S Manoukian; S Morassutt; D Morrone; J Nori; A Orlacchio; F Pane; P Panzarola; R Ponzone; G Simonetti; P Torricelli; G Valeri
Journal:  Radiol Med       Date:  2008-10-16       Impact factor: 3.469

Review 2.  Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines.

Authors:  M B Taylor; N R Bromham; S E Arnold
Journal:  Br J Radiol       Date:  2012-02-28       Impact factor: 3.039

3.  Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.

Authors:  Gary V Walker; Grace L Smith; George H Perkins; Julia L Oh; Wendy Woodward; Tse-Kuan Yu; Kelly K Hunt; Karen Hoffman; Eric A Strom; Thomas A Buchholz
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

4.  A unique presentation of occult primary breast cancer with a review of the literature.

Authors:  Inaya Ahmed; Kavita Dharmarajan; Amy Tiersten; Ira Bleiweiss; Hank Schmidt; Sheryl Green; Richard L Bakst
Journal:  Case Rep Oncol Med       Date:  2015-03-18

5.  Anemia and thrombocytopenia as initial symptoms of occult breast cancer with bone marrow metastasis: A case report.

Authors:  Lulu Liu; Jingjing Zhang; Mingtai Chen; Saisai Ren; Haihui Liu; Hao Zhang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

Review 6.  An occult urothelial carcinoma with wide multiorgan metastases and its genetic alteration profiling: Case report and literature review.

Authors:  Kunpeng Bu; Zeyan Shi; Yang Lu; Juan Zhao; Bixun Li
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Axillary Nodal Metastases from Carcinoma of Unknown Primary (CUPAx): Role of Contrast-Enhanced Spectral Mammography (CESM) in Detecting Occult Breast Cancer.

Authors:  Melania Costantini; Rino Aldo Montella; Maria Paola Fadda; Giorgia Garganese; Alba Di Leone; Alejandro Martin Sanchez; Gianluca Franceschini; Pierluigi Maria Rinaldi
Journal:  J Pers Med       Date:  2021-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.